[DEBUG-WINDOW 처리영역 보기]
BRIC을 시작페이지로 회원가입    로그인
BRIC한국을 빛내는 사람들
배너1 배너2 스폰서배너광고 안내
오늘의 BRIC정보
트위터 페이스북
검색 뉴스레터 안내
좋은 연구문화 만들기
Bio일정 프리미엄(유료) 등록이란?
2018 IUBMB SEOUL Plenary Lecture VOD
바이오 형광사진
실험의 달인들
Biojob 프리미엄(유료) 등록이란?
대메뉴안내: 한빛사
한빛사논문 추천논문 상위피인용논문 한빛사인터뷰 한빛사그이후 한빛사통계
김광수 (Kwang-Soo Kim) 저자 이메일 보기
Harvard Medical School
조회 834  인쇄하기 주소복사 트위터 공유 페이스북 공유 
[Commentary]Toward neuroprotective treatments of Parkinson’s disease

Kwang-Soo Kima,b,1

Molecular Neurobiology Laboratory, Program in Neuroscience, Harvard Medical School, Boston, MA 02115;
bDepartment of Psychiatry, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478

Parkinson’s disease (PD) is, after Alzheimer’s disease, the second most-common neurodegenerative disorder affecting 1-2% of the global population over the age of 65 (1, 2). Aging being a primary risk factor for PD (3), its economic burden on our society in terms of medical care will escalate with our aging population. The major pathophysiological features of PD include selective and progressive degeneration of A9 midbrain dopaminergic (mDA) neurons in the substantia nigra and widespread accumulation of intraneuronal proteinaceous inclusions, called Lewy bodies, whose major component is misfolded α-synuclein. A9 DA neurons project to the dorsal striatum and form the nigrostriatal pathway, which controls voluntary movements. Degeneration of this pathway in PD patients results in decreased dopamine levels in the striatum, leading to clinical manifestations, such as resting tremor, rigidity, bradykinesia, and gait dysfunctions (1, 2). Since its introduction in the 1960s, dopamine replacement therapy through levodopa (l-dopa) and DA agonist administration remain the standard treatment for PD (4). Although this pharmacological treatment dramatically improves the quality of life of numerous PD patients, its efficacy wanes over time and the need for increased dosage eventually induces severe side effects, such as dyskinesia. Although there are alternative surgical treatments, such as deep brain stimulation (5), both forms of treatment are symptomatic and cannot stop or modify the disease progression. Therefore, there is a significant unmet need for the development of novel neuroprotective and disease-modifying therapeutics for PD. In PNAS, Spathis et al. (6) introduce a novel compound, BRF110, which is a unique Nurr1: retinoid X receptor-α (RXRα)-selective “agonist” that can prevent DA neurons’ demise and striatal DA denervation in vivo in several preclinical models of PD. Remarkably, this study shows that BRF110 is not only neuroprotective in sparing mDA neurons, but also upon a single administration led to significant …

1To whom correspondence may be addressed.

- 형식: Commentary
- 게재일: 2017년 03월 (BRIC 등록일 2017-03-31)
- 연구진: 국외연구진
  댓글 0
김광수 님 전체논문보기 >
고지윤 (한양대학교)
김덕중 (Harvard Medical School)
김도훈 (Harvard Medical School)
김천형 (서울대학교)
문지숙 (차의과학대학교, Harvard M...)
이미옥 (한국생명공학연구원)
이상훈 (한양대학교)
이용희 (한양대학교)
장미윤 (McLean Hospital/Harvard M...)
정상미 (McLean Hospital/Harvard M...)
차영 (McLean Hospital/Harvard Med...)
차혁진 (서강대학교)
한민준 (St. Jude Children’s Rese...)
한백수 (한국생명공학연구원, Harva...)
황동연 (Harvard Medical School)
Google (by Kwang-Soo Kim)
Pubmed (by Kwang-Soo Kim)
프리미엄 Bio일정 Bio일정 프리미엄 안내
강북삼성병원 개원 50주년 기념 국제심포지엄
강북삼성병원 개원 50주년 기념 국제심포지엄
사전접수: ~2018.07.18
날짜: 2018.07.20
장소: 중앙일보빌딩 호암아트홀 (서울시 중구 서소문로 100)
의료기기 임상시험의 이해 과정
의료기기 임상시험의 이해 과정
날짜: 2018.06.27~29
장소: 경기도 성남시 분당구 판교역로 182 한국반도체산업협회 건물 9층
[The 12th Catholic International Stem Cell Symposium] 제12차 가톨릭국제줄기세포심포지엄
[The 12th Catholic International Stem Cell Symposium] 제12차 가톨릭국제줄기세포심포지엄
초록접수: ~2018.06.10
사전접수: ~2018.06.24
날짜: 2018.06.29
장소: 가톨릭대학교 성의교정 마리아홀(서울 반포)
이전페이지로 돌아가기 맨위로 가기

BRIC 홈    BRIC 소개    회원    검색    문의/FAQ    광고    후원
Copyright © BRIC. All rights reserved. Contact member@ibric.org